Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascale Cornillet-Lefebvre

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Transplantation|July 26, 2005
Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV statusHélène A Poirel, Alain Bernheim, Anouck Schneider, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood|July 2, 2002
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH)Nicole Dastugue, Marina Lafage-Pochitaloff, Marie-Pierre Pagès, et al.
Orphanet Journal of Rare Diseases|April 27, 2016
Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disordersVeronique Latger-Cannard, Christophe Philippe, Alexandre Bouquet, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Blood|February 3, 2005
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMSEric Deconinck, Charles Foussard, Noel Milpied, et al.
Blood Advances|May 24, 2024
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemiaAnne-Charlotte Le Floch, Florence Orlanducci, Marie-Christine Béné, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Transplantation|July 26, 2005
Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV statusHélène A Poirel, Alain Bernheim, Anouck Schneider, et al.
Haematologica|February 26, 2015
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialNicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Blood|July 2, 2002
Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogénétique Hématologique (GFCH)Nicole Dastugue, Marina Lafage-Pochitaloff, Marie-Pierre Pagès, et al.
Orphanet Journal of Rare Diseases|April 27, 2016
Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disordersVeronique Latger-Cannard, Christophe Philippe, Alexandre Bouquet, et al.
Oncotarget|September 20, 2019
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Oncotarget|May 27, 2017
NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Haematologica|August 27, 2013
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupSarah Bertoli, Pierre Bories, Marie C Béné, et al.
Blood|February 3, 2005
High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMSEric Deconinck, Charles Foussard, Noel Milpied, et al.
Blood Advances|May 24, 2024
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemiaAnne-Charlotte Le Floch, Florence Orlanducci, Marie-Christine Béné, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Pageof 5